

Nanosystems in Treating Lung Cancer

Subjects: [Medicine](#), [General & Internal](#)

Contributor: Alexandra Craciun

Even though there are various types of cancer, this pathology as a whole is considered the principal cause of death worldwide. Lung cancer is known as a heterogeneous condition, and it is apparent that genome modification presents a significant role in the occurrence of this disorder. There are conventional procedures that can be utilized against diverse cancer types, such as chemotherapy or radiotherapy, but they are hampered by the numerous side effects. Owing to the many adverse events observed in these therapies, it is imperative to continuously develop new and improved strategies for managing individuals with cancer. Nanomedicine plays an important role in establishing new methods for detecting chromosomal rearrangements and mutations for targeted chemotherapeutics or the local delivery of drugs via different types of nano-particle carriers to the lungs or other organs or areas of interest.

[lung cancer](#)[nanoparticles](#)[nanosystems](#)[liposomes](#)[dendrimers](#)[polymers](#)[micelles](#)[inorganic nanoparticles](#)[siRNA delivery systems](#)[biocompatibility](#)

1. Introduction

Cancer, in general, is a major cause of mortality on a global scale. This intricate pathology is characterized by inherent genetic alterations and cellular disorders, denoting an abnormal and uncontrollable cellular growth, eventually leading to the death of the patient [\[1\]\[2\]\[3\]](#).

According to the World Health Organization, Europe accounts for 23.4% of global cancer cases and 20.3% of cancer deaths [\[4\]\[5\]](#). Lung, breast, and colorectum cancer are the top five cancer types in terms of mortality. The majority of the newly discovered cases are related to lung and breast cancer [\[6\]](#). Lung cancer is responsible for the most significant number of deaths out of all cancer types due to the treatment difficulties and the poor prognosis on a worldwide scale, also representing the leading cause of cancer death in men. Lung cancer can be classified into two categories, depending on the cell morphology [\[7\]\[8\]](#). Non-small cell lung carcinoma (NSCLC) is considered an aggressive type of cancer, but NSCLC itself pales in comparison to small cell lung carcinoma (SCLC) in terms of aggressiveness [\[1\]\[3\]\[5\]\[9\]](#).

Tumors can either be removed from the body, even during their early stages of development, or treated via non-invasive methods [\[10\]](#). For example, lung cancer can be managed by various fundamental methods, each with its own set of limitations: for one, surgery cannot always lead to complete removal, whereas radiation therapy may cause a reduction of tumor size, but it too will never lead to complete eradication, and photodynamic therapy or

chemotherapy represent different methods that can be employed for advanced-stage lung cancer [11][12][13]. Moreover, radiation therapy and chemotherapy indiscriminately affect the cancerous cells, as well as the healthy tissues [14][15]. Another crucial aspect that should be taken into consideration is that radiation therapy and chemotherapy have various side effects, such as anemia, neutropenia, nausea, diarrhea, and other gastrointestinal symptoms, and to reduce the severity and frequency of these events requires the intake of additional drugs [16]. The typically late diagnosis and the standard treatments, which are characterized by many side effects and a lack of personalized therapy contribute to the high mortality, factors reinforcing the necessity to develop a new approach for this condition [17][18][19].

2. Nanosystems Involved in Treating Lung Cancer

Even if the early symptoms of lung cancer may be frequently overlooked, and the late stages of this condition could become inoperable, there are still just two main cancer drug therapies based on nanotechnology approved by the Food and Drug Administration: Abraxane and Genexol-PM [20].

Used in several types of cancer (such as breast, pancreatic, or non-small-cell lung cancer), Abraxane mainly consists of paclitaxel bound by albumin in the form of nanoparticles. Considered alone or combined in chemotherapy, this medicine proved to be effective as part of the lung cancer cure, showing milder adverse effects and great tolerability when administered alone [21] as a chemotherapeutic agent or in conjunction with other traditional drugs, such as cisplatin [22] or carboplatin [23].

With the same active substance (paclitaxel), Genexol-PM is the second drug approved by FDA for usage in lung cancer treatment. The main difference between it and Abraxane is the nanocarrier, which, in the case of Genexol-PM, consists of a proprietary polymeric micelle technology, according to the producer's website. Unlike studies on Abraxane administration, the use of paclitaxel in the form of Genexol-PM seems to be more controversial. Even if there is clear evidence of a superior tolerance in comparison with plain paclitaxel administration [24], and studies show its remarkable efficacy in treating lung cancer [25][26], at least one study [27] highlighted that serious safety concerns need to be assessed in the future. Nevertheless, while phase III clinical studies are still ongoing, back in 2013, Genexol-PM was regarded as the most successful micellar formulation of paclitaxel [28], and considering there have been no other related FDA approvals up to the present, this statement should still be valid.

These two alternatives based on nanosystems available in the USA for the cure of lung cancer reflect the very beginning point where we are at the moment and also the fact that there is a great amount of research that still needs to be done in order to achieve new milestones in this direction. One of the most promising solutions would be the development of immunotherapies. Already becoming a notable emerging domain, it can be conveniently used in the form of novel formulations, such as combinations of drug-loaded nanoparticles and immune checkpoint inhibitors (ICIs) [29]. An elegant and encouraging solution to this issue was proposed by Ge and collaborators [30], in which Fe_3O_4 superparticles (SPs) would encapsulate and carry immune-adjuvant drugs to a magnetic-targeted site. Using complementary photothermal therapy (PTT) under near-infrared laser irradiation, this method could lead to both direct and indirect ways (*via* immune system activation) to significantly reduce the tumor volume.

Finally, with the drug resistance of tumors still being a major problem, one's genetic traits and the ability of physicians to address this issue remain important decisive factors [31]. Gene therapy came in response to this specific problem and offered a wide range of solutions, from the use of silencing (si) RNA or long-non-coding (lnc)RNA to avoid the synthesis of pro-tumoral proteins, to micro RNA (miRNA) administration for gene expression modulation or even the novel CRISPR/Cas9 system for very specific gene targeting [32], all of which may be, at any time, promising candidates for lung cancer therapy.

Conclusively, even if there is a wide range of possibilities available for lung cancer therapy development, the actual results are rather modest, and the entire process seems to be evolving heavily at the moment. The intra- and inter-individual heterogeneity of this disease, corroborated by the increased instability or low encapsulation efficiency of the nanocarriers and other safety-related issues mentioned above, remain important concerns that must be addressed in the future.

2.1. Organic Nanosystems

2.1.1. Lipid-Based Particles

Liposomes are distinguished by their unique structure, represented by the lipid bilayer. This lipid-based vesicle is similar to cellular membranes, has an augmented biocompatibility like other synthetic materials, and has the potential to be a useful drug vehicle, as it is intended to be a nanocarrier [33][34]. The research is focused on their utilization as nanocarriers of drugs with a high toxicity, such as those employed in oncology. Under these circumstances, liposomes can present a great advantage in terms of permitting the transport of specific agents and allowing for a controlled release of the drug within a particular organ [35][36][37]. Another advantage of using liposomes in therapy is that they protect the loaded drug from degradation and prevent undesirable exposure to the environment [38].

Liposomes can be classified according to their size, the number of bilayers, or the preparation method: multilamellar vesicles that consist of several lipid bilayers separated from one another by aqueous spaces, which are heterogenous in size: small unilamellar vesicles comprised of a single bilayer surrounding the entrapped aqueous space, possessing a diameter less than 100 nm; or large unilamellar vesicles composed of a single bilayer surrounding the entrapped aqueous space, with a diameter larger than 100 nm [32][39].

The release of the drug can be deliberately triggered by different techniques, such as ultrasound, light, magnetism, or hyperthermia. Several experts in the field attempted to modify the surface of the liposomes to improve their capability to target different types of cancer and accumulate at the site of the tumors, delivering a higher concentration of the drug [35][40][41][42]. Liposomes can also be employed to alter DNA, anticancer agents, and antibiotics to improve chemotherapy by adding specific molecules to their surface, according to the tumor type or gene delivery, these being the most encouraging tools for cancer gene therapy [43][44][45]. Currently, there are only two products available on the market that can be utilized for ovarian cancer and lymphoblastic leukemia [46].

Regarding liposome usage in lung cancer treatment, a specific and outstanding benefit noticed was the uniform particle size distribution with respect to liposome, operating as drug delivery agents. There are at least a few studies in which the biodistribution of these formulations was indicated as an evidently strong point for choosing them as medication carriers [47].

2.1.2. Polymer-Based Particles

Dendrimers are a unique class of highly branched macromolecules whose shape and size can be controlled. These polymeric molecules are made up of multiple branched monomers capable of self-organization [48][49]. Structurally, the dendrimers are constituted by three essential regions: a central core, branches, or end groups, and the surface is formed using convergent or divergent step-growth polymerization, starting from monomers [50]. The size of these polymeric nanostructures depends on the number of branching points, which can be controlled and begin from a spherical central core. The cavities shaped inside the core structure and folds of the branches form cages and channels [51]. The free ends of the dendrimer arrangement can be used to attach other molecules, such as liposomes, nanoparticles, carbon nanotubes, anticancer compounds, or radioligands, or they can be transformed into biocompatible compounds with a high bio-permeability and low cytotoxicity [52][53]. Dendrimers present a variety of qualities, such as a surface functionalization capability and monodispersity of size, which make them attractive candidates for gene therapy—due to their ability to enter the cells via endocytosis—or for drug delivery and anticancer therapy, including chemotherapy [54][55]. If we refer to dendrimers as nanocarriers for drug delivery, the specific drug molecules can be quickly included via ligand- or receptor-mediated endocytosis [49].

Dendrimers show many advantages, such as a high drug-loading capacity, nano-size, which is favorable for targeting, and the capability to improve the solubility of poorly soluble anti-neoplastic drugs [56][57]. Nevertheless, their intrinsic toxicity cannot be disregarded—all classes of dendrimers manifest cytotoxic and hemolytic characteristics. This toxicity is dependent on the specific features of dendrimers and is related to the surface end groups [55][58]. To minimize the toxicity, polyethylene glycol can be associated or conjugated, as it can improve the plasma circulation time and tumor accumulation through an enhanced permeability and retention [59]. Different varieties of dendrimers can be utilized for multiple purposes, such as drug-encapsulated dendrimers or dendrimer drug conjugates that boast several benefits over drug-encapsulated systems. These nanocarriers can pass through several delivery barriers using two distinct mechanisms: passive and active targeting [60].

Regarding lung cancer treatment management using dendrimers, several studies have already shown promising outcomes. Doxorubicin (DOX), Cis-diamminodichloridoplatinum (II) (CDDP), and cisplatin (cisPt) are just a few of the efficient anti-tumoral medications tested as loads for dendrimers that are worth mentioning [61].

Polymers can be divided into natural polymers, synthetic polymers, and microbial fermentation polymers, but only natural and synthetic ones can be used for nano delivery. Polymeric nanoparticles are solid, nanosized colloidal particles that consist of a biodegradable polymer that should be biocompatible and non-toxic [62][63][64]. These features are the most important when this nanoparticle is desired for use in drug delivery and gene therapy, as well as other applications. Natural polymers are obtained directly from natural resources, as opposed to synthetic polymers, which are modified or synthesized in the laboratory using different techniques and devices and are

frequently used for nanoparticle design and development [35][65]. The most widely used polymer is chitosan, whereas other polymers are extensively used in nanoparticle synthesis, including dextran, albumin, heparin, gelatin, or collagen. Natural polymeric nanoparticles are biocompatible and non-toxic; however, when this type of nanoparticle is delivered across different biological membranes, issues such as on-site stability and a local variation in pH levels may sometimes limit their usefulness [65][66][67].

Synthetic polymers, such as polylactic acid, polyglycolic acid, and polyhydroxybutyrate, or other families of polymers are usually employed and suitable for drug delivery due to their individual characteristics, such as biocompatibility and biodegradability [68][69]. Synthetic polymeric nanoparticles present a particularly excellent result in terms of the release of drugs within the lungs in a controlled manner. They are a good candidate for oral, intravenous, or combined administering because of their advantages: biocompatibility and biodegradability, inferior toxicity, and low cost of production in large quantities using multiple methods [35][64]. Based on their structural organization, polymeric nanoparticles can be divided into nanocapsules and nanospheres. There have been numerous attempts to deliver a variety of anticancer drugs using polymeric nanoparticles, considering the physicochemical properties of polymers, their degradation, and the accurate and controllable drug release rate [35][70]. Moreover, it is also possible to synthesize polymeric nanoparticles with specific sizes, shapes, and surface modifications, offering a heightened precision in delivering a particular drug. All these developments have established a new direction in cancer treatment [71][72]. There is a large number of polymeric nanoparticles that have already been used in different phases of clinical trials—Abraxane has been approved by the Food and Drug Administration (FDA) for the treatment of different types of malignancies, such as breast cancer, NSCLC, and pancreatic cancer, or BIND-014, which is the first targeted polymeric nanoparticle utilized for the treatment of metastatic melanoma and squamous cell carcinoma [73][74][75].

Regarding nanocapsules, the drug is dissolved or dispersed in a liquid core of oil or water, which is encapsulated by a solid polymeric membrane, or in the case of the nanospheres, the drug is dispersed/entrapped in the polymer matrix. In both cases, the absorption or chemical conjugation of the drug on the surface is possible. As mentioned above, among the most important characteristics for polymers are biocompatibility and biodegradability; being biodegradable, these polymers can be degraded into individual monomers inside the body and removed from the body through metabolic pathways [35][76][77].

Micelles are nanosized, spherical colloidal particles, and lipid nanostructures consist of a hydrophobic core and a hydrophilic shell. In an aqueous environment, micelles hide their hydrophobic groups inside the structure and expose hydrophilic groups, whereas inside environments rich in lipids, these nanostructures are organized in the opposite way [78][79][80]. Micelles represent another variant of nanosystem that can be used to treat and diagnose multiple types of cancer and deliver various anticancer agents. By producing different variations of these nanosystems, it will be possible to monitor the pathways of interest and to estimate the therapeutic response [35][81][82]. Micelles are an innovative drug delivery system due to their stability in physiological conditions, high and versatile loading capacity, high accumulation of drugs at the target site, and their possibility of functionalizing the end group [83]. Medications can be entrapped within the hydrophobic core or linked covalently to the shell of these nanosystems. Micelles are stable and have a prolonged circulation time within the bloodstream, evading host

defenses [84][85]. The nanocarriers' ability to circumvent passive targeting via the fenestrated vasculature of tumors can be improved by covalent conjugation with the polyethylene glycol of the micelles' surface. In an aqueous environment, the hydrophobic core of the micelles can solubilize water-insoluble drugs, and the shell of the micelles can adsorb polar molecules [83][86]. In contrast, drugs with an intermediate polarity can be distributed along with the surfactant molecules in intermediate positions. Many micelles that contain anticancer drugs are under clinical trials, and only one of these nanosystems is approved for treating breast cancer patients [84]. Specifically, with regard to cancer lung management, one of the greatest advantages posed by micelles are the facile methods used for modifying their surfaces and the great specificity shown by these adjusted particles for the lung tumor environment [87]. Docetaxel (DTXL), Paclitaxel, and cisPt in combination with etoposide (ETO) are some of the most important anti-tumoral drugs for which micelles served as nanocarriers in lung cancer treatment studies [88].

2.2. Inorganic Nanomaterials

Inorganic materials, such as gold, silver, silica, or platinum, are intensely used to produce metallic nanoparticles using different methods. The manufactured metallic nanoparticles present an organized three-dimensional arrangement [89][90]. They are more flexible than other types of nanoparticles because of the possibility of controlling their size, shape, structure, composition, assembly, or encapsulation. Even though metallic nanoparticles present several advantages, a series of shortcomings should be taken into consideration within specific biomedical applications, such as the impossibility of loading drugs into their structure, and the blood-related adverse effects and cytotoxicity, depending on their size, concentration, and time of exposure [91][92][38]. Of all metallic nanoparticles, gold nanoparticles are of great interest for biomedical applications and present an excellent efficiency against different types of cancer, low toxicity, and tunable optical properties that can be controlled and employed for the treatment and diagnosis of specific pathologies [92][93][94]. Gold nanoparticles are considered a suitable nanocarrier for the effective delivery of bioactive agents, drug delivery, or delivery of biomolecules, like proteins, DNA, and small interfering RNA (siRNA), bioassay detection or imaging [95][94]. The surface of gold nanoparticles can be functionalized with different ligands, such as peptides, proteins, or DNA. Gold nanoparticles are widely used in cancer therapy, including photothermal therapy, radiotherapy, or as angiogenesis inhibitions. The formation process of new blood vessels is also a remarkable opportunity for the use of gold nanoparticles in cancer therapy [96][97][98].

Non-Polymeric Particles

Gold nanoparticles are intensely studied in connection with lung cancer therapy and diagnosis. In combination with Methotrexate, gold nanoparticles produce a cytotoxic effect in lung carcinomas [47]. A high reactivity characterizes the surface of gold nanoparticles. Due to this property, the surface of these nanoparticles can be easily modified or conjugated with functional biomolecules or other materials [95][99]. Gold nanoparticles can be encapsulated in liposomes, conjugated with nucleotides, coated with different polymer layers, or utilized as the core for dendrimers [32]. As mentioned above, nanoparticles are used for the targeted delivery of gene molecules. Of interest is siRNA, which is less stable, and enzymes can be attached to the microenvironment. Nanoparticles have the possibility of altering the fate of siRNA upon in vivo administration [100][101][102]. The advantages of nanoparticles favor siRNA delivery across biological barriers, which can be achieved using different methods: siRNA can be conjugated on

the surface of nanoparticles via a gold–thiol bond or electrostatic interactions, or it can adhere to the surface of the nanoparticles using polymer layers [103][104]. Gold nanoparticles are already used as an siRNA carrier system. The most important properties of gold are that it is non-toxic and can form fine nanoparticles, which can be functionalized for efficient gene delivery [105]. Using electrostatic or covalent methods, siRNA can be bound on the surface of the metal. Polyvalent molecules of siRNA can be attached to the surface of gold nanoparticles via thiol groups. These kinds of particles are characterized by a higher stability [104]. If a polyethyleneimine coating is added to the gold nanoparticle, this could render it a perfect siRNA delivery system. The interaction between polyethyleneimine-capped gold nanoparticles and siRNA is electrostatic [106][107]. It is worth mentioning that gold nanoparticles with cationic polymer modifications are excellent gene delivery systems. Gold nanoparticles can become stimuli-responsive, and in this way, siRNA delivery is very efficient [108]. Additionally, researchers have also developed a system represented by a gold nanoparticle-based sensor capable of detecting lung cancer by analyzing the exhaled breath of the patient. Gold nanoparticles were tested as sensors and are capable of detecting lung cancer due to their histology. As sensors, they were capable of distinguishing between the subtypes of lung cancer [104][106][107][108][109][110][111].

Concerning pulmonary cancer management, gold nanoparticles have at least three important advantages. Firstly, gold nanomaterials can be used as a diagnostic tool, offering important advantages in comparison with traditional organic dyes, such as a minimal toxicity and insignificant quenching [112]. Finally, gold nanomaterials exhibit therapeutic effects *per se* due to their implications and use in Photodynamic therapies (PDTs), which have been studied extensively in the chapter on the therapeutic effects of nanomaterials in the current article [113].

Carbon nanotubes are nanosized, hollow, and graphite sheets that are rolled up into a tubular form and belong to the family of fullerenes. These structures are called single-walled carbon nanotubes, if characterized by the presence of a single graphene sheet, or multi-walled carbon nanotubes, if they are formed from several concentric graphene sheets [114]. The diameter of single-walled nanotubes range between 0.5–3 nm, and the length can vary between 20–1000 nm, and as for multi-walled carbon nanotubes, the dimensions are 1.5–100 nm and 1–50 microns, respectively. Single-walled and multi-walled carbon nanotubes can be utilized as nanocarriers for specific drug delivery due to their specific physicochemical and biological characteristics [114][115][116]. Some of these characteristics may include a nanoneedle shape, hollow monolithic structure, high mechanical strength, high electrical and thermal conductivities, and also the ability to make surface adjustments [67]. The main disadvantage of carbon nanotubes as a drug nanocarrier is the poor water solubility and toxicity. The functionalization of carbon nanotubes is an essential key parameter in reducing the toxicity and maximizing the bioavailability of anticancer drugs, and carbon nanotubes are becoming an ideal nanocarrier for cancer therapy [67][117]. These nanostructures were intensively studied in recent years as a nanocarrier for anticancer drug delivery. There are many applications in which carbon nanotubes are very useful, such as gene delivery. The capacity of carbon nanotubes to transport DNA across the cell membrane is widely used in studies that involve gene therapy or gene silencing. A highly selective therapy is needed for cancer therapy, wherein tumor cells will be selectively modulated, so in this case, gene silencing may be performed using siRNA. However, delivering siRNA to specific cells is very problematic, given the instability of siRNA and their low uptake efficiency [91][96][77][73][118][119].

On the other hand, a crucial advantage of using these nano-sized materials in lung cancer treatment is their ability to enhance the effectiveness of chemotherapy, just by their plain administration in combination with such conventional anti-tumoral drugs. In addition, it was shown that using carbon nanotubes may prove to be effective in treating multidrug-resistant and/or radioresistant tumors, a fact that represents another important benefit of these materials [\[120\]](#). Several studies involving Gemcitabine, Curcumin, Paclitaxel, and DOX carried by carbon nanotubes demonstrated the great versatility of these inorganic materials in the context of their use as drug nanocarriers [\[121\]](#).

2.3. siRNA Delivery Systems

RNA interference was first discovered in plants in 2010, and later, the first small interfering delivery nanoparticle was created for effective use in humans. RNA interference is a defense mechanism, helping the eukaryotic cells to destroy the exogenous genes [\[122\]\[123\]](#). The double-stranded RNA enters the cell and is cleaved in short double-stranded fragments by the Dicer enzyme. Then, each double-stranded siRNA is split between the passenger and guide strands. The passenger strand is degraded, and the guide strand is incorporated into the RNA-induced silencing complex. The guide strand and the complementary sequence in mRNA lead to post-transcriptional gene silencing [\[109\]\[124\]\[125\]](#).

The inhibition of cellular pathways can be achieved with the help of siRNA. siRNA can destroy specific mRNA molecules and down-regulate the expression of many multidrug-resistant genes [\[126\]](#).

siRNA can target a multitude of undruggable genes, with kinases being the ones that have been validated for traditional small molecule drugs. In cancer, for example, genes are deregulated by high-level amplifications [\[127\]\[128\]](#). This kind of gene is of interest as a potential therapeutic target. Cancers are initially sensitive to chemotherapy and often adapt tolerance to targeted therapy by gene mutations [\[129\]](#). siRNA-based drug delivery is appealing, as it can target any mRNA of interest, and signs of progress have been shown for the development of siRNA-based drugs. There are many clinical trials regarding siRNA-based medicines that target the vascular endothelial growth factor (VEGF) pathway [\[130\]\[131\]\[132\]](#). Researchers have developed different vectors to improve RNA interference therapy in vivo, such as viral vectors, like the adenovirus, or non-viral vectors, which are seemingly the safer alternative. The principal characteristics of non-viral vectors should be their biocompatibility, intracellular uptake, specificity, and better half-life within the bloodstream [\[133\]](#). Many nanocarriers can be functionalized with different types of nanoparticles. Nanocarriers enter into the specific target cells and act through cellular pathways to deliver siRNA into the cytoplasm. Via endocytosis, nanocarriers are taken up by the cells. Endocytosis is not suitable for all nanocarriers, especially those containing drugs susceptible to lysosomal degradation [\[67\]\[134\]](#). Many strategies can be used to assist nanocarriers in escaping from degradation. For example, one of these is represented by the flip-flop mechanism. Scientists developed polyelectrolyte complex micelles that can be used as delivery systems for siRNA to silence the VEGF gene in cancer cells [\[135\]\[136\]](#).

The local administration of siRNA is an efficient and convenient method due to the prevention of systemic toxicity [\[137\]](#). The release of siRNA into the microenvironment of the cells or tissues transforms the siRNA into a biocompatible matrix, which is essential. Regarding lung cancer therapy, this delivery method has a critical role, because the therapeutic agent is transported to the bronchial airways, efficiently targeting the immune cells. The

therapeutic potential of siRNA is validated for use within in vivo applications. Though already mentioned, it should be repeatedly stressed that this delivery system has to be characterized by biocompatibility, biodegradability, and non-immunogenicity [\[114\]](#)[\[125\]](#).

3. Therapeutic Effects of Nanomaterials

The impressive versatility of nanomaterials is not solely based on their ability to deliver various compounds or genes in different dosages at specifically targeted sites [\[138\]](#). While research efforts were mainly channeled in this direction in the last decades, nano-sized materials can be regarded alone as valuable therapeutic agents. One curious example was already presented in the section on non-polymeric particles, where we mentioned the case of plain carbon nanotubes used as tools for chemotherapy potentiation. This effect may be due to the possible long-term immunostimulatory effects of the nanotubes, which was also observed in a similar study [\[120\]](#). In this section, we will describe two of the most intensely studied techniques that use nanoparticles as therapeutic agents or smart integrative nanoplateforms, rather than simple drug carriers.

3.1. Photothermal Therapy (PTT)

Already known for more than a couple of decays, one of the most intensely studied procedures involving nanosystems as active curing instruments is photothermal therapy (PTT). In simple terms, this method relies on the cancer cell lysis caused by the high temperature achieved in the tumoral tissue by exposure to near-infrared (NIR) light. The crucial role of the nanoagents in this operation is, evidently, to enhance the selectivity of heat production at the lesional site [\[91\]](#). By using nano-sized particles as NIR absorbents, the efficiency of the heat production in the tumoral microenvironment is significantly greater, and the lesional effect on the circumambient normal tissue would be minimized, not to mention the avoidance of unwanted systemic side effects [\[139\]](#).

Gold nanoshells were the very first such NIR absorbents used in PTT, with an evidence-based effectiveness. Developed in the mid-1990s as PEGylated silica-cored Au nanoshells, they later appeared in 2008 as absorbent agents for the AuroLase[®] Therapy (Nanospectra Biosciences, Houston, TX, USA) [\[140\]](#). The preclinical studies confirmed both the accumulation of these particles at the tumoral site and their effectiveness as light-to-heat conversion mediators. However, according to Nanospectra Biosciences, the proprietor of this technology, the nanoshells are currently only available for 'designated FDA sanctioned clinical studies'. Two clinical trials are being conducted at the moment to further investigate the safety and efficiency of these NIR absorbents [\[141\]](#).

Lately, materials such as semiconductors, graphene nanoparticles, polypyrrole nanoparticles, copper sulphide nanocrystals, and others are starting to be considered as possible alternatives as nano-sized light absorbents to noble metals [\[142\]](#). To avoid diversion from our main subject, we recommend the study of two comprehensive reviews on this matter, which best summarize the current aspects of nanomaterials used in PTT procedures.

3.2. Photodynamic Therapy (PDT)

Another emerging therapeutic solution that uses plain nanomaterials is Photodynamic therapy (PDT). The mechanism of action is already relatively well known, consisting basically of a photosensitizing (PS) agent being activated by light of a specific wavelength. After the photons activate the respective sensor, this will produce reactive singlet oxygen, which is largely known for its cellular cytotoxic effects. Using nano-sized materials as photosensitive agents for PDT implementation in cancer therapy would be a logical move to potentiate the specificity of this technique [143].

Interestingly, combining the use of nanoparticles and the PDT method encouraged the already known phenomena, called theranostics. This brand new concept suggests a synergy between diagnostics and therapy, a strategy that was proven to be easily achieved using nano-sized particles as PSs carriers in PTD [144].

Such an example would be the utilization of poly(vinyl alcohol)-porphyrin nanoparticles (PPNs). Specifically, those carriers function as PSs and are also able to transport antitumoral drugs (such as DOX-tested drugs in the cited experiment), which would be released at the tumoral site, once the PPNs are activated by NIR light. Not only did these smart nanoplateforms release active agents at the specific tumoral site, but they also combined PTT and PDT techniques to finally achieve a 100% survival rate in mice after 45 days of close observation and treatment. In addition, only one in six mice developed recurrent tumors [145]. Finally, a precision of approximately 95% was reported for these nanoparticles used as imaging tools, which may be involved in tumoral diagnostics and monitoring. Another interesting approach suggests the combination of inorganic materials using the PDT technique. Porphyrin-silica nanoparticles may be such an example, which proved to be useful due to both intense their fluorescence (that may be suitable for cell labelling) and sufficient reactive oxygen species (ROS) generation to inhibit tumor growth [146].

References

1. Frezzetti, D.; Gallo, M.; Maiello, M.R.; D'Alessio, A.; Esposito, C.; Chicchinelli, N.; Normanno, N.; De Luca, A. VEGF as a potential target in lung cancer. *Expert Opin. Ther. Targets* 2017, 21, 959–966.
2. What Is Lung Cancer?|CDC. (n.d.). Available online: https://www.cdc.gov/cancer/lung/basic_info/what-is-lung-cancer.htm (accessed on 24 June 2020).
3. Wu, X.; Ruan, L.; Yang, Y.; Mei, Q. Analysis of gene expression changes associated with human carcinoma-associated fibroblasts in non-small cell lung carcinoma. *Biol. Res.* 2017, 50, 6.
4. Global Cancer Observatory. (n.d.). Available online: <https://gco.iarc.fr/> (accessed on 15 May 2021).
5. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. *CA Cancer J. Clin.* 2015, 65, 87–108.

6. Cancer. (n.d.). Available online: https://www.who.int/health-topics/cancer#tab=tab_1 (accessed on 15 May 2021).
7. Dela Cruz, C.S.; Tanoue, L.T.; Matthay, R.A. Lung cancer: Epidemiology, etiology, and prevention. *Clin. Chest Med.* 2011, 32, 605–644.
8. Schabath, M.B.; Cote, M.L. Cancer Progress and Priorities: Lung Cancer. *Cancer Epidemiol. Biomark. Prev.* 2019, 28, 1563–1579.
9. Inamura, K. Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. *Front. Oncol.* 2017, 7, 193.
10. Arruebo, M.; Vilaboa, N.; Sáez-Gutierrez, B.; Lambea, J.; Tres, A.; Valladares, M.; González-Fernández, A. Assessment of the evolution of cancer treatment therapies. *Cancers* 2011, 3, 3279–3330.
11. Deng, X.; Shao, Z.; Zhao, Y. Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy. *Adv. Sci.* 2021, 8, 2002504.
12. Fan, Y.; Yu, D.; Li, D.; Wang, X. Prevention of Local Tumor Recurrence After Surgery by Thermosensitive Gel-Based Chemophotothermal Therapy in Mice. *Lasers Surg. Med.* 2020, 52, 682–691.
13. Parashar, B.; Arora, S.; Wernicke, A.G. Radiation therapy for early stage lung cancer. *Semin. Intervent. Radiol.* 2013, 30, 185–190.
14. Baskar, R.; Dai, J.; Wenlong, N.; Yeo, R.; Yeoh, K.W. Biological response of cancer cells to radiation treatment. *Front. Mol. Biosci.* 2014, 17, 24.
15. Baskar, R.; Lee, K.A.; Yeo, R.; Yeoh, K.W. Cancer and radiation therapy: Current advances and future directions. *Int. J. Med. Sci.* 2012, 9, 193–199.
16. MacDonald, V. Chemotherapy: Managing side effects and safe handling. *Can. Vet. J.* 2009, 50, 665–668.
17. Drug Delivery—Technical Platform—Creative Diagnostics. (n.d.). Available online: https://www.cd-bioparticles.com/t/Drug-Delivery_51.html (accessed on 8 June 2020).
18. Gautam, A.; van Veggel, F.C.J.M. Synthesis of nanoparticles, their biocompatibility, and toxicity behavior for biomedical applications. *J. Mater. Chem. B* 2013, 1, 5186–5200.
19. Lee, W.-H.; Loo, C.-Y.; Traini, D.; Young, P.M. Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges. *Asian J. Pharm. Sci.* 2015, 10, 481–489.
20. Ellis, P.M.; Vandermeer, R. Delays in the Diagnosis of Lung Cancer. *J. Thorac. Dis.* 2011, 3, 183–188.

21. Chen, H.; Xuewu, H.; Shutang, W.; Xinting, Z.; Jietao, L.; Peng, L.; Lizhu, L. Nab-Paclitaxel (Abraxane)-Based Chemotherapy to Treat Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Single Center, Randomized and Open-Label Clinical Trial. *Chin. J. Cancer Res.* 2015, 27, 190–196.
22. Dan, A.; Guan, Y.; Liu, X.J.; Zhang, C.-F.; Wang, P.; Liang, H.-L.; Guo, Q.-S. Clinical Comparative Investigation of Efficacy and Toxicity of Cisplatin plus Gemcitabine or plus Abraxane as First-Line Chemotherapy for Stage III/IV Non-Small-Cell Lung Cancer. *OncoTargets Ther.* 2016, 9, 5693–5698.
23. Socinski, M.A.; Bondarenko, I.; Karaseva, N.A.; Makhson, A.M.; Vynnychenko, I.; Okamoto, I.; Hon, J.K.; Hirsh, V.; Bhar, P.; Zhang, H.; et al. Weekly Nab-Paclitaxel in Combination with Carboplatin versus Solvent-Based Paclitaxel plus Carboplatin as First-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. *J. Clin. Oncol.* 2012, 30, 2055–2062.
24. Kim, T.-Y.; Kim, D.-Y.; Chung, J.-Y.; Shin, S.G.; Kim, S.-K.; Heo, D.S.; Kim, N.K.; Bang, Y.-J. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies. *Clin. Cancer Res.* 2004, 10, 3708–3716.
25. Kim, D.-W.; Kim, S.-Y.; Kim, H.-K.; Kim, S.-W.; Shin, S.W.; Kim, J.S.; Park, K.; Lee, M.Y.; Heo, D.S. Multicenter Phase II Trial of Genexol-PM, a Novel Cremophor-Free, Polymeric Micelle Formulation of Paclitaxel, with Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer. *Ann. Oncol.* 2007, 18, 2009–2014.
26. Lim, W.T.; Tan, E.H.; Toh, C.K.; Hee, S.W.; Leong, S.S.; Ang, P.C.S.; Wong, N.S.; Chowbay, B. Phase I Pharmacokinetic Study of a Weekly Liposomal Paclitaxel Formulation (Genexol®-PM) in Patients with Solid Tumors. *Ann. Oncol.* 2009, 21, 382–388.
27. Ahn, H.K.; Jung, M.; Sym, S.J.; Shin, D.B.; Kang, S.M.; Kyung, S.Y.; Park, J.W.; Jeong, S.H.; Cho, E.K. A Phase II Trial of Cremophor EL-Free Paclitaxel (Genexol-PM) and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer. *Cancer Chemother. Pharmacol.* 2014, 74, 277–282.
28. Ma, P.; Mumper, R.J. Paclitaxel Nano-Delivery Systems: A Comprehensive Review. *J. Nanomed. Nanotechnol.* 2013, 4, 6.
29. Deng, H.; Zhang, Z. The Application of Nanotechnology in Immune Checkpoint Blockade for Cancer Treatment. *J. Control Release* 2018, 290, 28–45.
30. Ge, R.; Liu, C.; Zhang, X.; Wang, W.; Li, B.; Liu, J.; Liu, Y.; Sun, H.; Zhang, D.; Hou, Y.; et al. Photothermal-Activatable Fe₃O₄ Superparticle Nanodrug Carriers with PD-L1 Immune Checkpoint Blockade for Anti-Metastatic Cancer Immunotherapy. *ACS Appl. Mater. Interfaces* 2018, 10, 20342–20355.

31. Rotow, J.; Bivona, T.G. Understanding and Targeting Resistance Mechanisms in NSCLC. *Nat. Rev. Cancer* 2017, 17, 637–658.
32. García-Fernández, C.; Fornaguera, C.; Borrós, S. Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy. *Cancers* 2020, 12, 1609.
33. Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifepour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K. Liposome: Classification, preparation, and applications. *Nanoscale Res. Lett.* 2013, 8, 102.
34. Gao, W.; Hu, C.M.; Fang, R.H.; Zhang, L. Liposome-like Nanostructures for Drug Delivery. *J. Mater. Chem. B* 2013, 1.
35. Patra, J.K.; Das, G.; Fraceto, L.F.; Campos, E.V.R.; Rodriguez-Torres, M.D.P.; Acosta-Torres, L.S.; Diaz-Torres, L.A.; Grillo, R.; Swamy, M.K.; Sharma, S.; et al. Nano based drug delivery systems: Recent developments and future prospects. *J. Nanobiotechnol.* 2018, 16, 71.
36. Ji, R.C. Lymph Nodes and Cancer Metastasis: New Perspectives on the Role of Intranodal Lymphatic Sinuses. *Int. J. Mol. Sci.* 2016, 18, 51.
37. Majumder, J.; Taratula, O.; Minko, T. Nanocarrier-based systems for targeted and site specific therapeutic delivery. *Adv. Drug Deliv. Rev.* 2019, 144, 57–77.
38. Lee, H.Y.; Mohammed, K.A.; Nasreen, N. Nanoparticle-based targeted gene therapy for lung cancer. *Am. J. Cancer Res.* 2016, 6, 1118–1134.
39. Bozzuto, G.; Molinari, A. Liposomes as nanomedical devices. *Int. J. Nanomed.* 2015, 10, 975–999.
40. Bi, H.; Xue, J.; Jiang, H.; Gao, S.; Yang, D.; Fang, Y.; Shi, K. Current developments in drug delivery with thermosensitive liposomes. *Asian J. Pharm. Sci.* 2019, 14, 365–379.
41. Deshpande, P.P.; Biswas, S.; Torchilin, V.P. Current trends in the use of liposomes for tumor targeting. *Nanomedicine* 2013, 8, 1509–1528.
42. Seynhaeve, A.L.B.; Amin, M.; Haemmerich, D.; van Rhoon, G.C.; Ten Hagen, T.L.M. Hyperthermia and smart drug delivery systems for solid tumor therapy. *Adv. Drug Deliv. Rev.* 2020, 163–164, 125–144.
43. Olusanya, T.O.B.; Haj Ahmad, R.R.; Ibegbu, D.M.; Smith, J.R.; Elkordy, A.A. Liposomal Drug Delivery Systems and Anticancer Drugs. *Molecules* 2018, 23, 907.
44. Wei, Q.Y.; Xu, Y.M.; Lau, A.T.Y. Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies. *Cancers* 2020, 12, 2783.
45. Yingchoncharoen, P.; Kalinowski, D.S.; Richardson, D.R. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. *Pharmacol. Rev.* 2016, 68, 701–

787.

46. Xing, H.; Hwang, K.; Lu, Y. Recent Developments of Liposomes as Nanocarriers for Theranostic Applications. *Theranostics* 2016, 6, 1336–1352.
47. Vinarov, Z.; Abrahamsson, B.; Artursson, P.; Batchelor, H.; Berben, P.; Bernkop-Schnürch, A.; Butler, J.; Ceulemans, J.; Davies, N.; Dupont, D.; et al. Current Challenges and Future Perspectives in Oral Absorption Research: An Opinion of the UNGAP Network. *Adv. Drug Deliv. Rev.* 2021, 171, 289–331.
48. Abbasi, E.; Aval, S.F.; Akbarzadeh, A.; Milani, M.; Nasrabadi, H.T.; Joo, S.W.; Hanifehpour, Y.; Nejati-Koshki, K.; Pashaei-Asl, R. Dendrimers: Synthesis, applications, and properties. *Nanoscale Res. Lett.* 2014, 9, 247.
49. Munavalli, B.B.; Naik, S.R.; Torvi, A.I.; Kariduraganavar, M.Y. Dendrimers. In *Functional Polymers; Jafar Mazumder, M., Sheardown, H., Al-Ahmed, A., Eds.; Polymers and Polymeric Composites: A Reference Series; Springer: Cham, Switzerland, 2019; pp. 289–345.*
50. Santos, A.; Veiga, F.; Figueiras, A. Dendrimers as Pharmaceutical Excipients: Synthesis, Properties, Toxicity and Biomedical Applications. *Materials* 2019, 13, 65.
51. Karimi, M.; Zangabad, P.S.; Mehdizadeh, F.; Malekzad, H.; Ghasemi, A.; Bahrami, S.; Zare, H.; Moghooei, M.; Hekmatmanesh, A.; Hamblin, M.R. Nanocaged platforms: Modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger. *Nanoscale* 2017, 9, 1356–1392.
52. Díaz, M.R.; Vivas-Mejia, P.E. Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes. *Pharmaceuticals* 2013, 6, 1361–1380.
53. Mody, N.; Tekade, R.K.; Mehra, N.K.; Chopdey, P.; Jain, N.K. Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: One platform assessment of drug delivery potential. *AAPS PharmSciTech* 2014, 15, 388–399.
54. Janaszewska, A.; Lazniewska, J.; Trzepiński, P.; Marcinkowska, M.; Klajnert-Maculewicz, B. Cytotoxicity of Dendrimers. *Biomolecules* 2019, 9, 330.
55. Pan, J.; Attia, S.A.; Filipczak, N.; Torchilin, V.P. 10—Dendrimers for drug delivery purposes. In *Nanoengineered Biomaterials for Advanced Drug Delivery; Masoud, M., Ed.; Woodhead Publishing Series in Biomaterials; Elsevier: Amsterdam, The Netherlands, 2020; pp. 201–242.*
56. Chis, A.A.; Dobrea, C.; Morgovan, C.; Arseniu, A.M.; Rus, L.L.; Butuca, A.; Juncan, A.M.; Totan, M.; Vonica-Tincu, A.L.; Cormos, G.; et al. Applications and Limitations of Dendrimers in Biomedicine. *Molecules* 2020, 25, 3982.
57. Madaan, K.; Kumar, S.; Poonia, N.; Lather, V.; Pandita, D. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. *J. Pharm. Bioallied Sci.* 2014, 6, 139–

150.

58. Palmerston Mendes, L.; Pan, J.; Torchilin, V.P. Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy. *Molecules* 2017, 22, 1401.
59. Gorain, B.; Choudhury, H.; Pandey, M.; Nair, A.B.; Amin, M.C.I.M.; Molugulu, N.; Deb, P.K.; Tripathi, P.K.; Khurana, S.; Shukla, R.; et al. Chapter 7—Dendrimer-Based Nanocarriers in Lung Cancer Therapy. In *Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer*; Prashant, K., Ed.; Academic Press: Cambridge, MA, USA, 2019; pp. 161–192.
60. Navya, P.N.; Kaphle, A.; Srinivas, S.P.; Bhargava, S.K.; Rotello, V.M.; Daima, H.K. Current trends and challenges in cancer management and therapy using designer nanomaterials. *Nano Converg.* 2019, 6, 23.
61. Bolhassani, A.; Javan zad, S.; Saleh, T.; Hashemi, M.; Aghasadeghi, M.R.; Sadat, S.M. Polymeric nanoparticles: Potent vectors for vaccine delivery targeting cancer and infectious diseases. *Hum. Vaccines Immunother.* 2014, 10, 321–332.
62. Idrees, H.; Zaidi, S.Z.J.; Sabir, A.; Khan, R.U.; Zhang, X.; Hassan, S.U. A Review of Biodegradable Natural Polymer-Based Nanoparticles for Drug Delivery Applications. *Nanomaterials* 2020, 10, 1970.
63. Mahapatro, A.; Singh, D.K. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. *J. Nanobiotechnol.* 2011, 9, 55.
64. Manavitehrani, I.; Fathi, A.; Badr, H.; Daly, S.; Negahi Shirazi, A.; Dehghani, F. Biomedical Applications of Biodegradable Polyesters. *Polymers* 2016, 8, 20.
65. Chenthamara, D.; Subramaniam, S.; Ramakrishnan, S.G.; Krishnaswamy, S.; Essa, M.M.; Lin, F.H.; Qoronfleh, M.W. Therapeutic efficacy of nanoparticles and routes of administration. *Biomater. Res.* 2019, 23, 20.
66. Chowdhury, A.; Kunjiappan, S.; Panneerselvam, T.; Somasundaram, B.; Bhattacharjee, C. Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases. *Int. Nano Lett.* 2017, 7, 91–122.
67. Din, F.U.; Aman, W.; Ullah, I.; Qureshi, O.S.; Mustapha, O.; Shafique, S.; Zeb, A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. *Int. J. Nanomed.* 2017, 12, 7291–7309.
68. Song, R.; Murphy, M.; Li, C.; Ting, K.; Soo, C.; Zheng, Z. Current development of biodegradable polymeric materials for biomedical applications. *Drug Des. Dev. Ther.* 2018, 12, 3117–3145.
69. Singh, R.; Lillard, J.W., Jr. Nanoparticle-based targeted drug delivery. *Exp. Mol. Pathol.* 2009, 86, 215–223.

70. Martinelli, C.; Pucci, C.; Ciofani, G. Nanostructured carriers as innovative tools for cancer diagnosis and therapy. *APL Bioeng.* 2019, 3, 011502.
71. Thakor, A.S.; Gambhir, S.S. Nanooncology: The future of cancer diagnosis and therapy. *CA Cancer J. Clin.* 2013, 63, 395–418.
72. Carpenter, A.W.; Schoenfisch, M.H. Nitric oxide release: Part II. Therapeutic applications. *Chem. Soc. Rev.* 2012, 41, 3742–3752.
73. Mourdikoudis, S.; Pallares, R.M.; Thanh, N.T.K. Characterization techniques for nanoparticles: Comparison and complementarity upon studying nanoparticle properties. *Nanoscale* 2018, 10, 12871–12934.
74. Draz, M.S.; Fang, B.A.; Zhang, P.; Hu, Z.; Gu, S.; Weng, K.C.; Gray, J.W.; Chen, F.F. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. *Theranostics* 2014, 4, 872–892.
75. Hanafy, N.A.N.; El-Kemary, M.; Leporatti, S. Micelles Structure Development as a Strategy to Improve Smart Cancer Therapy. *Cancers* 2018, 10, 238.
76. Begines, B.; Ortiz, T.; Pérez-Aranda, M.; Martínez, G.; Merinero, M.; Argüelles-Arias, F.; Alcudia, A. Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. *Nanomaterials* 2020, 10, 1403.
77. Jain, A.K.; Thareja, S. In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery. *Artif. Cells Nanomed. Biotechnol.* 2019, 47, 524–539.
78. Torchilin, V.P. Lipid-core micelles for targeted drug delivery. *Curr. Drug Deliv.* 2005, 2, 319–327.
79. Torchilin, V.P. Micellar nanocarriers: Pharmaceutical perspectives. *Pharm. Res.* 2007, 24, 1–16.
80. Bae, K.H.; Chung, H.J.; Park, T.G. Nanomaterials for cancer therapy and imaging. *Mol. Cells* 2011, 31, 295–302.
81. Lu, Y.; Zhang, E.; Yang, J.; Cao, Z. Strategies to improve micelle stability for drug delivery. *Nano Res.* 2018, 11, 4985–4998.
82. Suk, J.S.; Xu, Q.; Kim, N.; Hanes, J.; Ensign, L.M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. *Adv. Drug Deliv. Rev.* 2016, 99, 28–51.
83. Jhaveri, A.M.; Torchilin, V.P. Multifunctional polymeric micelles for delivery of drugs and siRNA. *Front. Pharmacol.* 2014, 5, 77.
84. Palazzolo, S.; Bayda, S.; Hadla, M.; Caligiuri, I.; Corona, G.; Toffoli, G.; Rizzolio, F. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes. *Curr. Med. Chem.* 2018, 25, 4224–4268.

85. Iravani, S.; Korbekandi, H.; Mirmohammadi, S.V.; Zolfaghari, B. Synthesis of silver nanoparticles: Chemical, physical and biological methods. *Res. Pharm. Sci.* 2014, 9, 385–406.
86. Zhang, Y.; Huang, Y.; Li, S. Polymeric micelles: Nanocarriers for cancer-targeted drug delivery. *AAPS PharmSciTech* 2014, 15, 862–871.
87. Sabir, F.; Qindeel, M.; Zeeshan, M.; Ain, Q.U.; Rahdar, A.; Barani, M.; González, E.; Aboudzadeh, M.A. Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review. *Processes* 2021, 9, 621.
88. Belani, C.P.; TAX 326 Study Group. Docetaxel in Combination with Platinums (Cisplatin or Carboplatin) in Advanced and Metastatic Non-Small Cell Lung Cancer. *Semin. Oncol.* 2002, 29, 4–9.
89. Shah, M.; Fawcett, D.; Sharma, S.; Tripathy, S.K.; Poinern, G.E.J. Green Synthesis of Metallic Nanoparticles via Biological Entities. *Materials* 2015, 8, 7278–7308.
90. Arvizo, R.; Bhattacharya, R.; Mukherjee, P. Gold nanoparticles: Opportunities and challenges in nanomedicine. *Expert Opin. Drug Deliv.* 2010, 7, 753–763.
91. Jeevanandam, J.; Barhoum, A.; Chan, Y.S.; Dufresne, A.; Danquah, M.K. Review on nanoparticles and nanostructured materials: History, sources, toxicity and regulations. *Beilstein J. Nanotechnol.* 2018, 9, 1050–1074.
92. Khan, I.; Saeed, K.; Khan, I. Nanoparticles: Properties, applications and toxicities. *Arab. J. Chem.* 2019, 12, 908–931.
93. Singh, P.; Pandit, S.; Mokkapati, V.R.S.S.; Garg, A.; Ravikumar, V.; Mijakovic, I. Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer. *Int. J. Mol. Sci.* 2018, 19, 1979.
94. Hougaard, K.S.; Campagnolo, L.; Chavatte-Palmer, P.; Tarrade, A.; Rousseau-Ralliard, D.; Valentino, S.; Park, M.V.; de Jong, W.H.; Wolterink, G.; Piersma, A.H.; et al. A perspective on the developmental toxicity of inhaled nanoparticles. *Reprod. Toxicol.* 2015, 56, 118–140.
95. Tiwari, P.M.; Vig, K.; Dennis, V.A.; Singh, S.R. Functionalized Gold Nanoparticles and Their Biomedical Applications. *Nanomaterials* 2011, 1, 31–63.
96. De Jong, W.H.; Borm, P.J. Drug delivery and nanoparticles: Applications and hazards. *Int. J. Nanomed.* 2008, 3, 133–149.
97. Ray, P.C.; Yu, H.; Fu, P.P. Toxicity and environmental risks of nanomaterials: Challenges and future needs. *J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev.* 2009, 27.
98. Yeh, Y.C.; Creran, B.; Rotello, V.M. Gold nanoparticles: Preparation, properties, and applications in bionanotechnology. *Nanoscale* 2012, 4, 1871–1880.

99. Lam, J.K.; Chow, M.Y.; Zhang, Y.; Leung, S.W. siRNA Versus miRNA as Therapeutics for Gene Silencing. *Mol. Ther. Nucleic Acids* 2015, 4, e252.
100. Li, D.; Gao, C.; Kuang, M.; Xu, M.; Wang, B.; Luo, Y.; Teng, L.; Xie, J. Nanoparticles as Drug Delivery Systems of RNAi in Cancer Therapy. *Molecules* 2021, 26, 2380.
101. Miele, E.; Spinelli, G.P.; Miele, E.; Di Fabrizio, E.; Ferretti, E.; Tomao, S.; Gulino, A. Nanoparticle-based delivery of small interfering RNA: Challenges for cancer therapy. *Int. J. Nanomed.* 2012, 7, 3637–3657.
102. Tortiglione, C.; de la Fuente, J.M. Synthesis of Gold Nanoparticles for Gene Silencing. *Methods Mol. Biol.* 2019, 1974, 203–214.
103. Graczyk, A.; Pawlowska, R.; Jedrzejczyk, D.; Chworos, A. Gold Nanoparticles in Conjunction with Nucleic Acids as a Modern Molecular System for Cellular Delivery. *Molecules* 2020, 25, 204.
104. Lee, S.K.; Han, M.S.; Asokan, S.; Tung, C.H. Effective gene silencing by multilayered siRNA-coated gold nanoparticles. *Small* 2011, 7, 364–370.
105. Kong, F.Y.; Zhang, J.W.; Li, R.F.; Wang, Z.X.; Wang, W.J.; Wang, W. Unique Roles of Gold Nanoparticles in Drug Delivery, Targeting and Imaging Applications. *Molecules* 2017, 22, 1445.
106. Song, W.J.; Du, J.Z.; Sun, T.M.; Zhang, P.Z.; Wang, J. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. *Small* 2010, 6, 239–246.
107. Mendes, R.; Fernandes, A.R.; Baptista, P.V. Gold Nanoparticle Approach to the Selective Delivery of Gene Silencing in Cancer-The Case for Combined Delivery? *Genes* 2017, 8, 94.
108. Babu, A.; Templeton, A.K.; Munshi, A.; Ramesh, R. Nanoparticle-Based Drug Delivery for Therapy of Lung Cancer: Progress and Challenges. *J. Nanomater.* 2013, 1–11.
109. Ramakrishnan, S. Hydrogel-siRNA for cancer therapy. *Cancer Biol. Ther.* 2011, 11, 849–851.
110. Waehler, R.; Russell, S.J.; Curiel, D.T. Engineering targeted viral vectors for gene therapy. *Nat. Rev. Genet.* 2007, 8, 573–587.
111. Aqel, A.; El-Nour, K.M.M.A.; Ammar, R.A.A.; Al-Warthan, A. Carbon nanotubes, science and technology part (I) structure, synthesis and characterisation. *Arab. J. Chem.* 2012, 5, 1–23.
112. Guinart, A.; Perry, H.L.; Wilton-Ely, J.D.E.T.; Tetley, T.D. Gold Nanomaterials in the Management of Lung Cancer. *Emerg. Top. Life Sci.* 2020, 4, 627.
113. Niculescu, A.G.; Grumezescu, A.M. Photodynamic Therapy—An Up-to-Date Review. *Appl. Sci.* 2021, 11, 3626.
114. Kobayashi, N.; Izumi, H.; Morimoto, Y. Review of toxicity studies of carbon nanotubes. *J. Occup. Health* 2017, 59, 394–407.

115. Szabó, A.; Perri, C.; Csató, A.; Giordano, G.; Vuono, D.; Nagy, J.B. Synthesis methods of carbon nanotubes and related materials. *Materials* 2012, 3, 3092–3140.
116. Zhang, W.; Zhang, Z.; Zhang, Y. The application of carbon nanotubes in target drug delivery systems for cancer therapies. *Nanoscale Res. Lett.* 2011, 6, 555.
117. Majumdar, R.; Rajasekaran, K.; Cary, J.W. RNA Interference (RNAi) as a Potential Tool for Control of Mycotoxin Contamination in Crop Plants: Concepts and Considerations. *Front. Plant Sci.* 2017, 8, 200.
118. Rizvi, S.A.A.; Saleh, A.M. Applications of nanoparticle systems in drug delivery technology. *Saudi Pharm. J.* 2018, 26, 64–70.
119. Attia, M.F.; Anton, N.; Wallyn, J.; Omran, Z.; Vandamme, T.F. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. *J. Pharm. Pharmacol.* 2019, 71, 1185–1198.
120. Madani, F.; Lindberg, S.; Langel, U.; Futaki, S.; Gräslund, A. Mechanisms of cellular uptake of cell-penetrating peptides. *J. Biophys.* 2011, 2011, 414729.
121. Salvioni, L.; Rizzuto, M.A.; Bertolini, J.A.; Pandolfi, L.; Colombo, M.; Prosperi, D. Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope. *Cancers* 2019, 11, 1855.
122. Xu, W.; Jiang, X.; Huang, L. 5.42—RNA interference technology. In *Comprehensive Biotechnology*, 2nd ed.; Murray, M.-Y., Ed.; Elsevier: Amsterdam, The Netherlands, 2019; pp. 560–575. ISBN 9780444640475.
123. Li, R.; Liu, T.; Wang, K. Hyaluronic modified and amine-functionalized silica nanoparticles as intracellular siRNA delivery carriers in lung cancer gene therapy. *Int. J. Clin. Exp. Med.* 2016, 9, 10191–10200.
124. Xu, C.; Wang, J. Delivery systems for siRNA drug development in cancer therapy. *Asian J. Pharma. Sci.* 2015, 10, 1–12.
125. Mansoori, B.; Mohammadi, A.; Davudian, S.; Shirjang, S.; Baradaran, B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. *Adv. Pharm. Bull.* 2017, 7, 339–348.
126. Bhullar, K.S.; Lagarón, N.O.; McGowan, E.M.; Parmar, I.; Jha, A.; Hubbard, B.P.; Rupasinghe, H.P.V. Kinase-targeted cancer therapies: Progress, challenges and future directions. *Mol. Cancer* 2018, 17, 48.
127. Dang, C.V.; Reddy, E.P.; Shokat, K.M.; Soucek, L. Drugging the ‘undruggable’ cancer targets. *Nat. Rev. Cancer* 2017, 17, 502–508.
128. Masoud, V.; Pagès, G. Targeted therapies in breast cancer: New challenges to fight against resistance. *World J. Clin. Oncol.* 2017, 8, 120–134.

129. de Fougerolles, A.; Vornlocher, H.P.; Maraganore, J.; Lieberman, J. Interfering with disease: A progress report on siRNA-based therapeutics. *Nat. Rev. Drug Discov.* 2007, 6, 443–453.
130. Hu, B.; Zhong, L.; Weng, Y.; Peng, L.; Huang, Y.; Zhao, Y.; Liang, X.J. Therapeutic siRNA: State of the art. *Signal Transduct. Target. Ther.* 2020, 5, 101.
131. Kim, Y.K. RNA Therapy: Current Status and Future Potential. *Chonnam Med. J.* 2020, 56, 87–93.
132. Patil, S.; Gao, Y.G.; Lin, X.; Li, Y.; Dang, K.; Tian, Y.; Zhang, W.J.; Jiang, S.F.; Qadir, A.; Qian, A.R. The Development of Functional Non-Viral Vectors for Gene Delivery. *Int. J. Mol. Sci.* 2019, 20, 5491.
133. Nelemans, L.C.; Gurevich, L. Drug Delivery with Polymeric Nanocarriers-Cellular Uptake Mechanisms. *Materials* 2020, 13, 366.
134. Conde, J.; Arnold, C.E.; Tian, F.; Artzi, N. RNAi nanomaterials targeting immune cells as an anti-tumor therapy: The missing link in cancer treatment? *Mater. Today* 2016, 19, 29–43.
135. Conde, J.; Tian, F.; Hernández, Y.; Bao, C.; Cui, D.; Janssen, K.P.; Ibarra, M.R.; Baptista, P.V.; Stoeger, T.; de la Fuente, J.M. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. *Biomaterials* 2013, 34, 7744–7753.
136. Mahmoodi Chalbatani, G.; Dana, H.; Gharagouzloo, E.; Grijalvo, S.; Eritja, R.; Logsdon, C.D.; Memari, F.; Miri, S.R.; Rad, M.R.; Marmari, V. Small interfering RNAs (siRNAs) in cancer therapy: A nano-based approach. *Int. J. Nanomed.* 2019, 14, 3111–3128.
137. Lam, J.K.; Liang, W.; Chan, H.K. Pulmonary delivery of therapeutic siRNA. *Adv. Drug Deliv. Rev.* 2012, 64, 1–15.
138. Lin, C.; Zhang, X.; Chen, H.; Bian, Z.; Zhang, G.; Riaz, M.K.; Tyagi, D.; Lin, G.; Zhang, Y.; Wang, J.; et al. Dual-Ligand Modified Liposomes Provide Effective Local Targeted Delivery of Lung-Cancer Drug by Antibody and Tumor Lineage-Homing Cell-Penetrating Peptide. *Drug Deliv.* 2018, 25, 256–266.
139. Madni, M.A.; Sarfraz, M.; Rehman, M.; Ahmad, M.; Akhtar, N.; Ahmad, S.; Tahir, N.; Ijaz, S.; Al-Kassas, R.; Löbenberg, R. Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications. *J. Pharm. Pharm. Sci.* 2014, 17, 401–426.
140. de Oliveira, S.A.; Borges, R.; dos Santos Rosa, D.; de Souza, A.C.S.; Seabra, A.B.; Bairo, F.; Marchi, J. Strategies for Cancer Treatment Based on Photonic Nano-medicine. *Materials* 2021, 14, 1435.
141. Amstad, E.; Gopinadhan, M.; Holtze, C.; Osuji, C.O.; Brenner, M.P.; Spaepen, F.; Weitz, D.A. NANOPARTICLES. Production of Amorphous Nanoparticles by Supersonic Spray-Drying with a Microfluidic Nebulator. *Science* 2015, 349, 956–960.

142. Leung, J.P.; Wu, S.; Chou, K.C.; Signorell, R. Investigation of Sub-100 Nm Gold Nanoparticles for Laser-Induced Thermotherapy of Cancer. *Nanomaterials* 2013, 3, 86–106.
143. Stern, J.M.; Solomonov, V.V.K.; Sazykina, E.; Schwartz, J.A.; Gad, S.C.; Goodrich, G.P. Initial Evaluation of the Safety of Nanoshell-Directed Photothermal Therapy in the Treatment of Prostate Disease. *Int. J. Toxicol.* 2016, 35, 38–46.
144. Kaus, N.H.M.; Rithwan, A.F.; Adnan, R.; Ibrahim, M.L.; Thongmee, S.; Yusoff, S.F.M. Effective Strategies, Mechanisms, and Photocatalytic Efficiency of Semiconductor Nanomaterials Incorporating RGO for Environmental Contaminant Degradation. *Catalysts* 2021, 11, 302.
145. Paszko, E.; Ehrhardt, C.; Senge, M.O.; Kelleher, D.P.; Reynolds, J.V. Nanodrug Applications in Photodynamic Therapy. *Photodiagnosis Photodyn. Ther.* 2011, 8, 14–29.
146. Mavridi-Printezi, A.; Guernelli, M.; Menichetti, A.; Montalti, M. Bio-Applications of Multifunctional Melanin Nanoparticles: From Nanomedicine to Nanocosmetics. *Nanomaterials* 2020, 10, 2276.

Retrieved from <https://encyclopedia.pub/entry/history/show/32238>